Conceptos Categóricos

MANEJO MEDICO DE LAS COMPLICACIONES HEMORRAGICAS EN CUIDADOS PALIATIVOS ONCOLOGICOS
Artículos relacionadosArtículos relacionadosArtículos relacionados
Artículos afines de siicsalud publicados en los últimos 4 meses

MANEJO MEDICO DE LAS COMPLICACIONES HEMORRAGICAS EN CUIDADOS PALIATIVOS ONCOLOGICOS

(especial para SIIC © Derechos reservados)
Las neoplasias pueden alterar el equilibrio hemostásico predisponiendo a la trombosis o a fenómenos hemorrágicos. Se describen las medidas terapéuticas para estos pacientes, así como sus indicaciones, complicaciones y aspectos prácticos.
ucedatorres9.jpg Autor:
María Elena Uceda Torres
Columnista Experto de SIIC

Institución:
U.G.C Molino de la Vega


Artículos publicados por María Elena Uceda Torres
Coautores
Juan Nicolás Rodríguez Rodríguez* Ana Cristina Rodríguez Rodríguez** 
Doctor en Medicina, Especialista en Hematología y Hemoterapia, U.G.C. Hematología. Hospital "Juan Ramón Jiménez", Huelva, España*
Licenciada en Medicina y Cirugía, Especialista en Medicina Familiar y Comunitaria, Centro de Salud de Arriondas, Asturias, España**
Recepción del artículo
9 de Abril, 2010
Aprobación
15 de Abril, 2010
Primera edición
30 de Junio, 2010
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Las neoplasias son ampliamente reconocidas como entidades capaces de alterar el equilibrio hemostásico del organismo predisponiendo fundamentalmente a la trombosis, aunque también pueden generarse fenómenos hemorrágicos. Este hecho obliga a los equipos de cuidados paliativos a realizar en ocasiones el diagnóstico y tratamiento de estas últimas eventualidades. El presente trabajo realiza primeramente una revisión de la fisiopatología de los fenómenos hemorrágicos en relación con los procesos tumorales y, posteriormente, de las medidas médicas disponibles destinadas al tratamiento de dichos fenómenos y que incluyen: antifibrinolíticos, transfusión de plaquetas, vitamina K, transfusión de plasma fresco congelado, factores específicos, concentrado de factores del complejo protrombínico o factor VII recombinante activado, con especial énfasis en sus indicaciones, complicaciones, problemas en el manejo y aspectos prácticos en este tipo de pacientes.

Palabras clave
hemorragia, hemorragia, cáncer, cáncer, neoplasias, neoplasias, cuidados paliativos, cuidados paliativos, tratamiento, tratamiento


Artículo completo

(castellano)
Extensión:  +/-8.19 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Neoplasms are widely recognized as circumstances that can produce an imbalance in the hemostatic equilibrium of the organism leading mainly to thrombosis, although a hemorrhagic process can also be produced. This latter circumstance means that palliative care units must face an eventual diagnosis and treatment of these hemorrhagic episodes. This paper performs both a review of the physiopathology of hemorrhages in cancer patients, and a review of which currently available medical measures can be used to treat these complications. These:include: antifibrinolytic agents, platelet transfusion, vitamin K, fresh frozen plasma transfusion, administration of specific clotting factors, prothrombin complex concentrates, and recombinant activated factor VII, with special emphasis on their indications, related complications, problems in application and practical aspects in this type of patients.

Key words
hemorrhage, hemorrhage, cancer, cancer, neoplasms, neoplasms, palliative care, palliative care treatment, treatment


Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Hematología, Oncología
Relacionadas: Atención Primaria, Bioética, Bioquímica, Cirugía, Diagnóstico por Laboratorio, Educación Médica, Emergentología, Enfermería, Farmacología, Geriatría, Medicina Familiar, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 8.19 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
María Elena Uceda Torres, U.G.C Molino de la Vega, 21003, Paseo de Santa Fe nº 8, 5º A, Huelva, España
Bibliografía del artículo


1. Johnson MJ. Bleeding, clotting and cancer. Clin Oncol 9:294-301, 1997.
2. Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am 10:457-484, 1996.
3. Falanga A, Barbui T. Coagulopathy of acute promyelotic leukemia. Acta Haematol 106:43-51, 2001.
4. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 60:3071-9, 1987.
5. Rogers LR. Cerebrovascular complications in cancer patients. Oncology (Huntingt) 8:23-30, 1994.
6. Kessler CM. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Semin Hematol 41(2 Suppl.3):10-4, 2004.
7. Murphy S. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost 78:622-626, 1997.
8. Neukirchen J, Blum S, Kuendgen A y col. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol 83:477-82, 2009.
9. Manoharan A, Brighton T, Gemmell R, Lopez K, Moran S, Kyle P. Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study. Int J Hematol 76:272-278, 2002.
10. Rosen PJ. Bleeding problems in cancer patients. Hematol Oncol Clin North Am 6:1315-1328, 1992.
11. Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol 22:129-136, 2009.
12. Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 22:153-163, 2009.
13. Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 118:417-422, 2006.
14. Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol 48(Supl.):S13-S16, 2003.
15. Davis MP. Hematology in palliative medicine. Am J Hosp Palliat Care 21:445-454, 2004.
16. DeSancho MT, Rand JH. Bleeding and thrombotic complications in critically ill patients with cancer. Crit Care Clin 17:599-622, 2001.
17. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 7(Suppl 1):9-12, 2009.
18. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, Van Vliet HH. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 32:589-604, 2006.
19. Girtovitis FI, Ntaios G, Papadopoulos A, Ioannidis G, Makris PE. Defective platelet aggregation in myelodysplastic syndromes. Acta Haematol 118:117-122, 2007.
20. Michiels JJ, Budde U, Van der Planken M, Van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, clasification and management. Best Pract Res Clin Haematol 14:401-436, 2001.
21. Glaspy JA. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am 6:1301-1314, 1992.
22. Hauser I, Lechner K. Solid tumors and factor VIII antibodies. Thromb Haemost 82:1005-1007, 1999.
23. Glassman AB. Hemostatic abnormalities associated with cancer and its therapy. Ann Clin Lab Sci 27:391-395, 1997.
24. Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 5:1364-1372, 1987.
25. Maurer HS, Steinherz PG, Gaynon PS y col. The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. J Clin Oncol 6:1425-1432, 1988.
26. Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist 9:561-570, 2004.
27. Dean A, Tuffin P. Fibrinolytic inhibitors for cancer-associated bleeding problems. J Pain Symptom Manage 13:20-24, 1997.
28. Schultz M, Van der Lelie H. Microscopic haematuria as a relative contraindication for tranexamic acid. Br J Haematol 89:663-664, 1995.
29. Manjunath G, Fozailoff A, Mitcheson D, Sarnak MJ. Epsilon-aminocaproic acid and renal complications: case report and review of the literature. Clin Nephrol 58:63-67, 2002.
30. Stefanini M, English HA, Taylor AE. Safe and effective, prolonged administration of epsilon aminocaproic acid in bleeding from the urinary tract. J Urol 143:559-561, 1990.
31. Seto AH, Dunlap DS. Tranexamic acid in oncology. Ann Pharmacother 30:868-870, 1996.
32. Algora M, Fernández A, Gómez JL y col. Guía sobre la indicación de la transfusión de glóbulos rojos, plaquetas y productos plasmáticos lábiles. Med Clin (Barc) 113:471-474, 1999.
33. Barbolla L, Richart A. Indicaciones clínicas de los componentes sanguíneos. Hematol Citocinas Inmunoter Ter Cel 2:335-353, 1999.
34. Schiffer CA, Anderson KC, Bennett CL, y col. Platelet transfusion for patients with cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538, 2001.
35. British Committee for the Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 122:10-23, 2003.
36. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 172-8, 2007.
37. Stanworth SJ, Hyde C, Brunskill S, Murphy MF. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now? Br J Haematol 131:588-95, 2005.
38. Marwaha N, Sharma RR. Consensus and controversies in platelet transfusion. Transfus Apher Sci 41:127-133, 2009.
39. Gmur J, Burger J, Schanz U, Fehr J, Schaffner J. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 338:1223-1226, 1991.
40. Friedman AM, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 16:34-45, 2002.
41. Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 91:1530-1537, 2006.
42. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 18:153-167, 2004.
43. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 142:348-360, 2008.
44. Kerkhoffs JL, Eikenboom JC, Van de Watering LM, Van Wordragen-Vlaswinkel RJ, Wijermans PW, Brand A. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 48:1959-1965, 2008.
45. Cartoni C, Brunetti GA, D'Elia GM y col. Cost analysis of a domiciliary program of supportive and palliative care for patients with hematologic malignancies. Haematologica 92:666-673, 2007.
46. Fanucchi M, Glaspy J, Crawford J y col. Effects of polyethylene glycol-conjugated recombinant human megakariocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336:404-409, 1997.
47. Basser R. The impact of thrombopoietin on clinical practice. Curr Pharm Des 8:369-377, 2002.
48. Ciurea SO, Hoffman R. Cytokines for the treatment of thrombocytopenia. Semin Hematol 44:166-182, 2007.
49. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol 46(1 Suppl.2):S26-S32, 2009.
50. Cohn CS, Bussel JB. Romiplostim: a second-generation thrombopoietin agonist. Drugs Today (Barc) 45:175-188, 2009.
51. Will B, Kawahara M, Luciano JP y col. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 114:3899-3908, 2009.
52. Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients. Semin Dial 22:279-286, 2009.
53. Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 3:138-153, 2007.
54. Rebulla P. Platelet transfusion trigger in difficult patients. Transfus Clin Biol 8:249-254, 2001.
55. Ministerio de Sanidad y Consumo. Indicaciones clínicas y riesgos del plasma fresco congelado. Med Clin (Barc) 102:225-227, 1994.
56. O'Shaughnessy DF, Atterbury C, Bolton Maggs P y col. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 126:11-28, 2004.
57. Agence Française de Sécurité Sanitaire des Produits de Santé. Transfusion de plasma frais congelé: produits, indications. Transfusion Clinique et Biologique 9:322-332, 2002.
58. Crosby E, Ferguson D, Hume HA y col. Guidelines for red blood cell and plasma transfusion for adult and children. Can Med Assoc J 156:S1-S4, 1997.
59. National Health and Medical Research Council (NHMRC) ASoBTA. Clinical Practice Guidelines on the use of Blood Components (red blood cells, platelets, fresh frozen plasma and cryoprecipitate). Avaliable at: www.nhmrc.health.gov.au, 2002.
60. Task Force on Blood Component Therapy. Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists. Anesthesiology 83:732-747, 1996.
61. Iorio A, Basileo M, Marchesini E y col. The good use of plasma. A critical analysis of five international guidelines. Blood Transfus 6:18-24, 2008.
62. Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 126:139-152, 2004.
63. Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology Am Soc Hematol Educ Program 179-86, 2007.
64. Gibson BE, Todd A, Roberts I y col. Transfusion guidelines for neonates and older children. Br J Haematol 124:433-453, 2004.
65. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care 12:R105, 2008.
66. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 100:557-562, 2008.
67. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 145:24-33, 2009.
68. Markman M. Common complications and emergencies associated with cancer and its therapy. Cleve Clin J Med 61:105-114; quiz 162, 1994.
69. Webb IJ, Anderson KC. Risks, costs, and alternatives to platelet transfusions. Leuk Lymphoma 34:71-84, 1999.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
Artículos relacionadosMás relacionadosAtículos relacionados
ua31618
-->